Oncodesign closed an agreement with GSK to acquire the François Hyafil Research Centre located in Villebon-sur-Yvette (Essonne), including transfer of the team of the highly qualified drug discovery staff (approx. 57 people). Under the terms of the agreement, GSK will provide €35 million support over a four year period. Funds will allow Oncodesign to integrate the site and its capabilities into its business.

Established in 1987 and located in a new state-of-the-art research facility opened in 2010, the François Hyafil Research Centre was most recently a Flexible Discovery Unit of GSK. The facility includes delivery of medicinal chemistry, biology, in vivo pharmacology and drug metabolism/pharmacokinetics capabilities with experience in many therapeutic areas.